Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, have emerged as important tools in the management of metabolic health. Originally developed for type 2 diabetes, these therapies are now widely studied for their effects on weight management, cardiovascular risk reduction and broader metabolic outcomes.
This article reviews the current evidence, clinical considerations and practical guidance for incorporating GLP-1 agonists into patient care
What Are GLP-1 Agonists?
GLP-1 agonists are synthetic analogues of the naturally occurring incretin hormone GLP-1. They work by:
– Stimulating insulin secretion in a glucose-dependent manner
– Suppressing glucagon release
– Slowing gastric emptying
– Promoting satiety and reducing appetite
These mechanisms contribute to improved glycaemic control and reduced caloric intake, supporting weight loss and metabolic health
Evidence for Efficacy
Numerous clinical trials have evaluated the efficacy of GLP-1 agonists in both diabetes management and weight loss. Key findings include:
– Significant reductions in HbA1c levels
– Clinically meaningful weight loss (up to 15–22% in some studies)
– Improvements in cardiovascular risk markers
– Positive effects on lipid profiles and blood pressure
Clinical Considerations
When prescribing GLP-1 agonists, healthcare professionals should consider:
– **Patient selection:** Assess medical history, contraindications and treatment goals.
– **Dosing and titration:** Follow evidence-based dosing schedules to minimise side effects.
– **Monitoring:** Track weight, glycaemic control and tolerability.
– **Ongoing support:** Provide education and regular follow-up to optimise outcomes.
Conclusion
GLP-1 agonists represent a significant advancement in the management of metabolic health, with robust evidence supporting their use in appropriate patients. As research continues, these therapies are likely to play an increasingly important role in comprehensive metabolic care.